Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOv19-BBz CAR T Cells in FRa+ Cancers
NCT07116057Phase 1Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Oct 2025
- Primary completion
- Oct 2040
- Countries
- 1
01
Overview
Phase 1, open-label trial of MOv19-BBz in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Pennsylvania. Primary endpoints: Incidence of adverse events at 15 years and Occurrence of treatment-limiting toxicities at 28 days. Started Oct 2025; status: recruiting.
02
Drugs
MOv19-BBz
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07116057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116057.